AKT1 and neoplasm: Moreover, BEZ-235 has been shown to inhibit PI3K/mTOR-dependent signaling nodes such as AKT, S6, and 4EBP1, reducing MMP-2 expression and invasive migration across multiple tumor types [31,32].